Fierce Pharma

SEPTEMBER 26, 2024

After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan successor, Gazyva, is chasing new horizons in active lupus nephritis. | In a phase 3 study called REGENCY, a statistically higher proportion of lupus nephritis patients treated with biannual intravenous Gazyva doses and standard autoimmune disease therapy achieved complete renal responses at 76 weeks compared to those treated with standard therapy alone, Genentech reported Thur

Patients 223

Patients 223

pharmaphorum

SEPTEMBER 26, 2024

Our periodic round-up of financings in the biotech sector is led by an impressive nine-figure round for UK vaccines developer Vicebio, with GC Therapeutics, Genespire, and 858 Therapeutics also in on the action.London, UK-based Vicebio raised $100 million in a Series B that will help to fund the development of its Molecular Clamp technology to produce improved, more potent vaccines that are simpler to manufacture.

Manufacturing 103

Manufacturing 103

Fierce Pharma

SEPTEMBER 26, 2024

The days of broad stomach cancer labels for PD-1 inhibitors appear to be numbered. | The days of broad stomach cancer labels for PD-1 inhibitors appear to be numbered. A group of external advisers to the FDA voted 10-2 that the use of PD-1 inhibitors in first-line, HER2-negative gastric cancer is not favorable in patients who have PD-L1-negative tumors.

FDA 210

FDA Patients 210

MedCity News

SEPTEMBER 26, 2024

Following a months-long dispute, data platform Particle Health filed an antitrust lawsuit against Epic, alleging that the EHR giant is using its dominance in the market to prevent competition in the payer platform space. Particle believes the lawsuit is an “unprecedented challenge” to Epic’s market power, while Epic thinks the startup’s claims are “baseless.

Competition 106

Competition Marketing Patients 106

Advertisement

Fierce Pharma

SEPTEMBER 26, 2024

In June, at the American Society of Clinical Oncology (ASCO) conference in Chicago, when AstraZeneca discussed results from a phase 3 trial of its non-small cell lung cancer (NSCLC) blockbuster Tag | In June at the ASCO conference in Chicago, when AstraZeneca discussed results from a phase 3 trial of its non-small cell lung cancer blockbuster Tagrisso, the presentation received a standing ovation.

FDA 185

FDA 185

MedCity News

SEPTEMBER 26, 2024

Dr. Timothy Showalter talks about how AI can be a powerful force in recommending treatment for cancer patients. He is Artera’s chief medical officer and the company has built a digital pathology tool for prostate cancer patients. The post MedCity Pivot Podcast: How AI Can Help in Cancer appeared first on MedCity News.

Medical 100

Medical Patients 100

MedCity News

SEPTEMBER 26, 2024

BioAge Labs’ lead drug candidate, azelaprag, is in Phase 2 testing in combination with Eli Lilly’s weight management medication Zepbound. The biotech’s oral drug activates a receptor it says can mimic certain biological effects of exercise. The post Exercise Benefit in a Pill: BioAge Labs Goes Public, Raising More Than $200M for Clinical Trials appeared first on MedCity News.

Management 100

Management Leads Medical Biopharma 100

pharmaphorum

SEPTEMBER 26, 2024

Flagship Pioneering's latest biotech launch, Mirai Bio, aims to help genetic medicine developers find the best way to get their drugs to patients.The new Cambridge, Massachusetts-based company – which was set up in 2021 but makes its official launch today with $50 million in funding from Flagship – applies artificial intelligence to solve the various obstacles that can block the progress of new medicines.

Medicine 94

Medicine 94

MedCity News

SEPTEMBER 26, 2024

Don’t miss this opportunity to gain valuable knowledge and practical insights on how employers are addressing an increasingly complex healthcare budget landscape. The post Battle of the Budget: Employers vs. Rising Healthcare Costs appeared first on MedCity News.

Healthcare 91

Healthcare Healthcare 91

pharmaphorum

SEPTEMBER 26, 2024

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%. The expansion of the listing reflects the massive investor appetite for companies with assets in the clinic for obesity and takes the on-paper value of the Richmond, California-based company above $600 million.

89

89

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

MedCity News

SEPTEMBER 26, 2024

Through a new partnership, employees of BetterHelp’s employer clients can access Talkiatry’s psychiatry services on an in-network basis at no extra cost. The post BetterHelp, Talkiatry Collaborate To Offer Psychiatric Services to Employers appeared first on MedCity News.

Networking 87

Networking 87

pharmaphorum

SEPTEMBER 26, 2024

IntraBio claims FDA approval for its Aqneursa therapy for Niemann-Pick type C, the second new drug for the disease in four days

Patients 103

Patients FDA 103

MedCity News

SEPTEMBER 26, 2024

Responsible procurement and handling of data and digital marketing insights by hospitals can generate useful information to improve patient wellness and operational efficiency without compromising compliance. The post Personalize Patient Care with Confidence Through Efficient, HIPAA-Compliant Data Usage appeared first on MedCity News.

Patients 77

Patients Marketing 77

pharmaphorum

SEPTEMBER 26, 2024

AstraZeneca's EGFR inhibitor Tagrisso has been approved by the FDA for a new lung cancer indication that could make it a go-to therapy for a patient population that until now had no targeted treatments. The US regulator has cleared Tagrisso (osimertinib) for patients with stage 3 non-small cell lung cancer (NSCLC) expressing EGFR exon 19 or exon 21 (L858R) mutations that cannot be treated with surgery and has been previously treated with chemoradiotherapy.

FDA 85

FDA Patients 85

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition

MedCity News

SEPTEMBER 26, 2024

To effectively address health disparities, organizations must implement health equity strategies that target systemic barriers and root causes. Here are strategies that can help drive comprehensive, system-wide change. The post How Health Systems Can Bridge Gaps in Health Equity appeared first on MedCity News.

Healthcare 65

Healthcare Healthcare 65

pharmaphorum

SEPTEMBER 26, 2024

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable (MSS) metastatic colorectal cancer.An analysis of data from the 447-patient KEYFORM-007 study revealed that the fixed-dose combination of Keytruda (pembrolizumab) and favezelimab was unable to extend overall survival (OS) compared to standard care with kinase inhibitor regorafenib and trifluridine and tipirac

Patients 79

Patients 79

PharmaTech

SEPTEMBER 26, 2024

In this podcast episode, we discuss both the challenges of and the progress made so far by the biopharma industry toward non-parenteral means of delivering biologic drugs.

Biopharma 64

Biopharma 64

PharmaVoice

SEPTEMBER 26, 2024

Roivant CEO Matt Gline leads the company on a unique path by placing bets on misfit drugs and technologies — and it’s working.

Leads 64

Leads 64

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

PharmaTech

SEPTEMBER 26, 2024

In this episode of the Ask the Expert video series, Peter Walters, Fellow of Advanced Therapies at CRB Group, discusses factors to be considered in constructing a new facility for cell and gene therapy production as well as using an existing facility to expand cell and gene therapy pipelines.

59

59

PharmExec

SEPTEMBER 26, 2024

Tagrisso was approved under a Priority Review based on the pivotal LAURA Phase III trial in adults with unresectable stage III epidermal growth factor receptor-mutated non-small cell lung cancer.

FDA 52

FDA 52

PharmaTech

SEPTEMBER 26, 2024

The EcoPositive range, which comprises 50% of Bormioli Pharma’s current standard catalog and is composed of three distinct sustainability approaches, offers more than 3000 industrial solutions, in glass and plastic.

Pharma 52

Pharma 52

European Pharmaceutical Review

SEPTEMBER 26, 2024

New global guidance on best practices to improve clinical trials has been released by the World Health Organization (WHO). Fundamentally, the document offers approaches aimed at enhancing the design, conduct and oversight of clinical trials, to strengthen country-led R&D ecosystems. The guidance is relevant to clinical trials including pharmaceutical medicines, vaccines, behavioural and psychological interventions, preventive care, as well as digital and public health approaches and traditio

Safety 52

Safety Pharmaceutical Medicine Patients 52

Advertisement

Distribution

PharmExec

SEPTEMBER 26, 2024

In this part of his Pharmaceutical Executive video interview,Jonathan Scheinberg, of the Northeast Science and Technology Center, talks about strategies companies can adopt to attract and retain top talent in these competitive mega campus locations.

Competition 52

Competition Pharmaceutical 52

European Pharmaceutical Review

SEPTEMBER 26, 2024

This year, PharmaLab Congress will be offering a diverse programme to professionals from analytical and microbiological quality control in the pharmaceutical industry, from contract laboratories, authorities and service providers. In 2022 and 2023, PharmaLab attracted more participants to Düsseldorf/Neuss than ever before. On the back of this success, the 12th PharmaLab Congress will again be held on site in Düsseldorf/Neuss from 25-27 November 2024.

Pharmaceutical 52

Pharmaceutical Pharmaceutical products Safety 52

Pharmatutor

SEPTEMBER 26, 2024

Raising Awareness About Breast Carcinoma : A Critical Public Health Priority admin Thu, 09/26/2024 - 16:11 About Author Devansh Mehta, Founder Director of TRM WRITER’S LLP AND MARKETMAVERICKS DIGITAL OPC PVT LTD Address : Flat no.

52

52

Pharmaceutical Technology

SEPTEMBER 26, 2024

West Pharmaceutical Services is a winner in the Safety category in the 2024 Pharmaceutical Technology Excellence Awards.

Pharmaceutical 66

Pharmaceutical Safety 66

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

PharmExec

SEPTEMBER 26, 2024

A new JAMA study indicates that semaglutide produced up to a 68% lower risk of opioid overdose for patients with type 2 diabetes compared to other antidiabetic medications.

Patients 52

Patients Medical 52

PharmaTech

SEPTEMBER 26, 2024

A new Center of Excellence will be established at PCI Pharma Services’ location in Rockford, Ill., and two sites in Ireland will also benefit from the investment.

Pharma 52

Pharma 52

PharmExec

SEPTEMBER 26, 2024

Omnichannel marketing can help companies improve HCP engagement to facilitate the delivery of effective treatment to patients who desperately need and deserve it.

Marketing 52

Marketing Patients 52

PharmaTimes

SEPTEMBER 26, 2024

New government scheme to offer routine opt-out blood tests

Government 80

Government 80

Advertiser: ZoomInfo

In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.

Marketing